Contact us 24/7
View all

Archillion Hepatitis Drug Raises Concern over Liver Injuries

Destiny Baker3 years ago

As pharmaceutical companies race to get FDA approval on new hepatitis C drugs, a clinical trial hold placed on Archillion's ACH-3102 due to abnormal liver enzyme levels may mark the end of the drug. However, like many companies, Archillion has more hepatitis C drugs in the pipeline.

Archillion Pharmaceutical Clinical Trial Hold

  • According to Bloomberg, a hepatitis drug by Archillion Pharmaceutical Inc. (ACH-3102) has been placed on hold by U.S. regulators.
  • The hold is in response to reports of elevated enzymes in a trial in which the drug was combined with two medications used in the treatment of HIV.
  • Elevated enzymes can represent an irregularity which may result in renal injury or even death.
  • Though one clinical trial is on hold, Archillion still has two other hepatitis C drugs in the pipeline.

Market Shares Fall as Clinical Trial is Placed on Hold

  • With an estimated market worth of $20 billion, the development of a new hepatitis C drug would mean huge profits for both a pharmaceutical company and that company’s investors.
  • Further, with so many companies racing to develop a new hepatitis C drug, a clinical trial hold often spells doom for a potential drug as market shares begin to drop.
  • As Archillion’s ACH-3102 was place on hold, the company saw a 25% decline in shares.
  • Similarly, Vertex saw a 19% decline with its last hold and Idenix a 30% drop.
Hepatitis C Drugs Currently in Clinical Development

According to HCV Advocates, 12 pharmaceutical companies currently have 28 hepatitis C drugs in clinical trials.

  •     Achillion
  •     AbbVie
  •     Boehringer Ingelheim
  •     Bristol Myers-Squibb
  •     Genentech
  •     Gilead
  •     Merck
  •     Tibotec
  •     Janssen Pharmaceuticals
  •     Vertex
Contact an Experienced Product Liability Attorney

Thomas J. Henry are leaders in the area of drug and product liability litigation. Our Defective Drug and Products Division have extensive knowledge and resources in order to represent our clients efficiently and aggressively. The Defective Drug and Products Division represent a multitude of people who are battling against manufacturers of medical devices and/ or defective pharmaceuticals.

If you or a loved one have been injured by or have developed serious side-effects from the use of defective medications or medical devices, contact Thomas J. Henry immediately. We represent clients/victims all over the country. We are available 24/7, nights and weekends.


If you’ve been injured, we can help. Contact us